Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility

"Double-hit" and "double-expressor" lymphomas represent distinct but overlapping subsets of aggressive B-cell non-Hodgkin lymphoma. The high rates of bone marrow involvement by these lymphomas pose a major therapeutic challenge due to the chemotherapy-resistant nature of the bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Craig, Jeffrey W., Mina, Michael J., Crombie, Jennifer L., LaCasce, Ann S., Weinstock, David M., Pinkus, Geraldine S., Pozdnyakova, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051601/
https://www.ncbi.nlm.nih.gov/pubmed/30020951
http://dx.doi.org/10.1371/journal.pone.0199708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051601/
https://www.ncbi.nlm.nih.gov/pubmed/30020951
http://dx.doi.org/10.1371/journal.pone.0199708

Ejemplares similares